Reverse Transcriptase Inhibitors
"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
| Descriptor ID |
D018894
|
| MeSH Number(s) |
D27.505.519.389.675.850 D27.505.954.122.388.077.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".
This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 6 | 1 | 7 |
| 2012 | 3 | 1 | 4 |
| 2013 | 6 | 2 | 8 |
| 2014 | 3 | 2 | 5 |
| 2015 | 5 | 1 | 6 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.
-
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
-
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).
-
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients. Br J Clin Pharmacol. 2024 Nov; 90(11):2947-2952.
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
-
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
-
High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):130-137.
-
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther. 2021 04; 109(4):1034-1044.
-
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine (Baltimore). 2020 Sep 11; 99(37):e21661.
-
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
-
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis. S Afr Med J. 2019 Nov 27; 109(12):919-926.